Results 41 to 50 of about 345,042 (281)

Investigating the Factors Affecting Out-of-Pocket in Hospitals Affiliated to Mazandaran University of Medical Sciences

open access: yesRāhburdhā-yi Mudīriyyat dar Niẓām-i Salāmat, 2019
Background: Out-of-pocket is one of the most important payment methods in Iran's health system, which has negative impacts on equity and pushes the vulnerable groups into poverty.
Niloofar Alikhani   +2 more
doaj  

IJCM_202A: Catastrophic health expenditure (CHE) due to diabetes mellitus among urban slum population of Agra city- An Observational study

open access: yesIndian Journal of Community Medicine
Background: People with diabetes need extensive self-management support, medications, regular screening for and treatment of possible complications and comorbidities, all of which can increase out-of-pocket (OOP) costs in patients and their families ...
Lingareddy Prathyusha   +3 more
doaj   +1 more source

Cytoplasmic p21 promotes stemness of colon cancer cells via activation of the NFκB pathway

open access: yesMolecular Oncology, EarlyView.
Cytoplasmic p21 promotes colorectal cancer stem cell (CSC) features by destabilizing the NFκB–IκB complex, activating NFκB signaling, and upregulating BCL‐xL and COX2. In contrast to nuclear p21, cytoplasmic p21 enhances spheroid formation and stemness transcription factor CD133.
Arnatchai Maiuthed   +10 more
wiley   +1 more source

Households of tuberculosis (TB) patients face high TB-related costs in Somalia

open access: yesBMC Global and Public Health
Background The out-of-pocket spending and costs incurred by households affected by tuberculosis (TB) while accessing TB services in Somalia remain unclear.
Joseph Kuye   +11 more
doaj   +1 more source

IJCM_236A: Out-of-pocket expenditure on healthcare among geriatric population in central Kerala

open access: yesIndian Journal of Community Medicine
Background: India is facing dual challenges caused by a rapid increase in burden of non-communicable diseases, marking epidemiological transition and an unprecedented expansion of geriatric population.
Merin Mariam Roy, Jose Vincent
doaj   +1 more source

Plecstatin inhibits hepatocellular carcinoma tumorigenesis and invasion through cytolinker plectin

open access: yesMolecular Oncology, EarlyView.
The ruthenium‐based metallodrug plecstatin exerts its anticancer effect in hepatocellular carcinoma (HCC) primarily through selective targeting of plectin. By disrupting plectin‐mediated cytoskeletal organization, plecstatin inhibits anchorage‐dependent growth, cell polarization, and tumor cell dissemination.
Zuzana Outla   +10 more
wiley   +1 more source

Determination of Direct and Indirect Costs Incurred by Tuberculosis Patients During Diagnosis and Treatment in Urban Areas of South Gujarat: A Mixed Method Approach

open access: yesIndian Journal of Community Medicine
Though many initiatives and monetary benefits are incorporated under RNTCP/NTEP, many patients might incur some out-of-pocket expenditure (OOP) related to diagnosis, treatment, and hospitalization. Such costs lead to further poverty and default.
Rutu Buch, Rahul Damor, J. K. Kosambiya
doaj   +1 more source

Burden of out-of-pocket expenditure for road traffic injuries in urban India

open access: yesBMC Health Services Research, 2012
Background Road traffic injuries (RTI) are an increasing public health problem in India where out-of-pocket (OOP) expenditures on health are among the highest in the world. We estimated the OOP expenses for RTI in a large city in India.
Kumar G   +3 more
doaj   +1 more source

An Overdose of Out‐of‐Pocket Expenses [PDF]

open access: yesThe Milbank Quarterly, 2014
It's one of the most important studies in the history of research about health care. It's also one of the most frequently misunderstood, and most commonly misapplied, studies.
openaire   +2 more sources

Recurrent cancer‐associated ERBB4 mutations are transforming and confer resistance to targeted therapies

open access: yesMolecular Oncology, EarlyView.
We show that the majority of the 18 analyzed recurrent cancer‐associated ERBB4 mutations are transforming. The most potent mutations are activating, co‐operate with other ERBB receptors, and are sensitive to pan‐ERBB inhibitors. Activating ERBB4 mutations also promote therapy resistance in EGFR‐mutant lung cancer.
Veera K. Ojala   +15 more
wiley   +1 more source

Home - About - Disclaimer - Privacy